Skip to main content

Scilex Holding Co

corporate_fare Company Profile

Scilex Holding Co

SCLX·NASDAQ·Life Sciences·CIK 0001820190

The Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain. The company targets indications with high unmet needs and large market opportunities. Its commercial products include ZTlido® (lidocaine topical system) 1.8%, an FDA-approved prescription lidocaine topical product for neuropathic pain associated with postherpetic neuralgia (PHN), a form of post-shingles nerve pain. Another product is ELYXYB®, an FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. GLOPERBA®, the first and only liquid oral version of the anti-gout medicine colchicine for the prophylaxis of painful gout flares in adults, launched in June 2024. The company also has three product candidates. SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) ("SEMDEXA™") is a novel, viscous gel formulation of a corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which a Phase 3 study has been completed. SP-103 (lidocaine topical system) 5.4% ("SP-103") is a next-generation, triple-strength formulation of ZTlido for acute pain, with a completed Phase 2 trial in acute low back pain (LBP). Lastly, SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) ("SP-104") is a novel low-dose delayed-release naltrexone hydrochloride being developed for fibromyalgia, for which Phase 1 trials were completed.

Scilex Holding Co (NASDAQ:SCLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for SCLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for SCLX spans 8-K, 4, 10-Q, SCHEDULE 13D/A.

Recent high-impact activity:

  • Scilex Hit With Nasdaq Notice: Market Value Below $35M Minimum, All Three Listing Standards Failed
  • Scilex Dismisses Auditor BPM, Appoints Pipara & Co. Amid Going-Concern Doubts
  • Scilex Taps $15.8M from Vivasor Credit Line, Paying with 50M Datavault AI Shares
  • Scilex Posts $115M Q2 Loss, Cash Dwindles to $0.6M, Going Concern Doubt Reiterated
  • Scilex Unwinds Vivasor Stake in $12M Related-Party Sale

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$30.25M
Net Income
-$374.05M
Diluted EPS
-$36.48
Op. Cash Flow
$3.82M
Free Cash Flow
$3.68M
Gross Profit
$125.8M
Operating Income
-$346.01M
Cash & Equivalents
$4.96M
Total Debt
$83.26M
Debt / Equity
-0.40×
Net Margin
-12.36×
Shares Outstanding
7.03M sh
Source: 10-K · filed 2026-04-10 · accession 0001193125-26-151455

Short Interest & Short Volume

3.37 days to cover

FINRA reported short interest of 132,205 shares in SCLX as of the October 30, 2026 settlement, a 10.9% decrease from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 40.3% of SCLX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)132,205 shares as of October 30, 2026
Change vs prior period▼ 10.9%
Days to cover3.37 at avg daily volume of 39,269
Daily short volume (FINRA facilities)40.3% of 141,539 shares on November 20, 2026
5-day average short volume42.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SCLX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.

1 shelf registration

Equity Incentive Plan Expanded · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$0.6003 -7.65% today
52-week range · as of 2026-11-20 $0.50 – $16.81
Market cap
$3.98M
Volume
198.3K (2.7× avg)
3-mo avg 72.9K
Live data · 2026-11-21 13:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SCLX - Latest Insights

SCLX
Nov 20, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5658
Real-time Price: $0.6003 info
Change: +$0.0345 (+6%) info
Market Cap: $3.98M info
SCLX
Nov 17, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.642
Real-time Price: $0.6003 info
Change: -$0.0417 (-6%) info
Market Cap: $3.98M info
SCLX
Aug 24, 2026, 4:12 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $5.66
Real-time Price: $0.6003 info
Change: -$5.06 (-89%) info
Market Cap: $3.98M info
SCLX
Aug 14, 2026, 4:41 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.76
Real-time Price: $0.6003 info
Change: -$6.16 (-91%) info
Market Cap: $3.98M info
SCLX
Jul 22, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.03
Real-time Price: $0.6003 info
Change: -$6.43 (-91%) info
Market Cap: $3.98M info
SCLX
Jul 07, 2026, 9:26 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $0.6003 info
Change: -$8.90 (-94%) info
Market Cap: $3.98M info
SCLX
Jul 06, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.08
Real-time Price: $0.6003 info
Change: -$8.48 (-93%) info
Market Cap: $3.98M info
SCLX
Jun 29, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.80
Real-time Price: $0.6003 info
Change: -$7.20 (-92%) info
Market Cap: $3.98M info
SCLX
Jun 24, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.86
Real-time Price: $0.6003 info
Change: -$6.26 (-91%) info
Market Cap: $3.98M info
SCLX
Jun 02, 2026, 5:09 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $7.40
Real-time Price: $0.6003 info
Change: -$6.80 (-92%) info
Market Cap: $3.98M info
SCLX
May 20, 2026, 5:22 PM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $6.01
Real-time Price: $0.6003 info
Change: -$5.41 (-90%) info
Market Cap: $3.98M info
SCLX
May 05, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $10.83
Real-time Price: $0.6003 info
Change: -$10.23 (-94%) info
Market Cap: $3.98M info
SCLX
May 05, 2026, 1:24 PM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $11.00
Real-time Price: $0.6003 info
Change: -$10.40 (-95%) info
Market Cap: $3.98M info
SCLX
May 05, 2026, 1:00 PM EDT
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $11.49
Real-time Price: $0.6003 info
Change: -$10.89 (-95%) info
Market Cap: $3.98M info
SCLX
Apr 30, 2026, 4:55 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $10.50
Real-time Price: $0.6003 info
Change: -$9.90 (-94%) info
Market Cap: $3.98M info
SCLX
Apr 28, 2026, 4:58 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.25
Real-time Price: $0.6003 info
Change: -$6.65 (-92%) info
Market Cap: $3.98M info
SCLX
Apr 27, 2026, 10:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $6.82
Real-time Price: $0.6003 info
Change: -$6.22 (-91%) info
Market Cap: $3.98M info
SCLX
Apr 20, 2026, 8:56 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $0.6003 info
Change: -$6.40 (-91%) info
Market Cap: $3.98M info
SCLX
Apr 20, 2026, 8:52 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $0.6003 info
Change: -$6.40 (-91%) info
Market Cap: $3.98M info
SCLX
Apr 16, 2026, 5:11 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $6.59
Real-time Price: $0.6003 info
Change: -$5.99 (-91%) info
Market Cap: $3.98M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets